RedHill Biopharma (NASDAQ:RDHL) Shares Cross Below 200 Day Moving Average – Time to Sell?

RedHill Biopharma Ltd. (NASDAQ:RDHL)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $142.87 and traded as low as $6.83. RedHill Biopharma shares last traded at $6.87, with a volume of 11,804 shares.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on RedHill Biopharma in a report on Saturday, August 24th. They set a “hold” rating for the company.

RedHill Biopharma Price Performance

The stock’s 50-day simple moving average is $8.54 and its 200 day simple moving average is $142.87.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.